Valeritas Presents Positive CBD h-Patch™ Data at the 2nd Annual International Cannabinoid-Derived Pharmaceuticals Summit

BRIDGEWATER, N.J., Sept. 12, 2019 (GLOBE NEWSWIRE) — Valeritas Holdings, Inc. (NASDAQ: VLRX), a medical technology company and maker of the V-Go® Wearable Insulin Delivery device, which uses its proprietary h-Patch™ technology, announced today positive data from a preclinical pharmacokinetic (PK) study of cannabidiol (CBD) subcutaneous infusion was presented at the 2nd Annual International Cannabinoid-Derived Pharmaceuticals Summit in Boston, Massachusetts. Data presented at the Summit showed rapid and robust absorption and distribution of 40mg CBD delivered over 24 hours with the h-Patch™ technology. CBD was detected within one hour of the start of infusion, followed by prolonged elimination with near steady state levels still detectable 24 hours after completion of h-Patch™ infusion, or 48 hours in total. These data demonstrated that subcutaneous infusion of CBD of 40mg with the h-Patch™ provided peak plasma levels on

... read more at: http://www.globenewswire.com/news-release/2019/09/12/1914647/0/en/Valeritas-Presents-Positive-CBD-h-Patch-Data-at-the-2nd-Annual-International-Cannabinoid-Derived-Pharmaceuticals-Summit.html

by

Leave a Reply